Hesham A. Hassaballa on Medika Life

This Is Why We Should NEVER Rush A Vaccine To Market

According to a new poll, registered voters’ skepticism has grown, and this is bad news

We need a vaccine for Covid-19. It is a matter of life and death. At the same time, that vaccine has to be proven to be safe and effective, and if one gets rushed to market — especially if it’s timed for the general election — then I have said previously that I will not take it.

According to a recent CBS News poll, that same skepticism has grown among registered voters:

Just 21% of voters nationwide now say they would get a vaccine as soon as possible if one became available at no cost, down from 32% in late July. Most would consider it but would wait to see what happens to others before getting one.

In July, 51% said they would take a “wait and see” approach, and now that number has grown to 58%. Also, the proportion of people who said they will never take a Covid-19 vaccine increased from 17% to 21%. That’s one in five people.

This is bad news.

For there to be any possible return to “normal” life — something akin to what we had pre-pandemic — we need as many people as possible immune to the SARS-CoV-2 virus. And the easiest way for us to get to that coveted “herd immunity,” without losing more than 2 million Americans, is to have as many people vaccinated against SARS-CoV-2.

If this vaccine is rushed to market, there will not be enough trust from people — myself included — for the vaccine to be effective at curbing the pandemic. This is of critical importance, and that is why I am heartened by the statement put out by several vaccine developers that they will not bow to political pressure:

Following guidance from expert regulatory authorities such as FDA regarding the development of COVID-19 vaccines, consistent with existing standards and practices, and in the interest of public health, we pledge to:

Always make the safety and well-being of vaccinated individuals our top priority.

Continue to adhere to high scientific and ethical standards regarding the conduct of clinical trials and the rigor of manufacturing processes.

Only submit for approval or emergency use authorization after demonstrating safety and efficacy through a Phase 3 clinical study that is designed and conducted to meet requirements of expert regulatory authorities such as FDA.

Work to ensure a sufficient supply and range of vaccine options, including those suitable for global access.

We believe this pledge will help ensure public confidence in the rigorous scientific and regulatory process by which COVID-19 vaccines are evaluated and may ultimately be approved.

I hope they stay true to this pledge.

Vaccines are an amazing thing, and they have saved us from the devastating effects of several devastating illnesses. That said, they need to be proven to be safe and effective. Rushing out a vaccine to satisfy the political monster is wrong on so many levels. And if the public doesn’t trust the vaccine, we are not getting out of this nightmare any time soon.

PATIENT ADVISORY

Medika Life has provided this material for your information. It is not intended to substitute for the medical expertise and advice of your health care provider(s). We encourage you to discuss any decisions about treatment or care with your health care provider. The mention of any product, service, or therapy is not an endorsement by Medika Life

Dr. Hesham A. Hassaballa
Dr. Hesham A. Hassaballahttp://drhassaballa.com
Dr. Hesham A. Hassaballa is a NY Times featured Pulmonary and Critical Care Medicine specialist in clinical practice for over 20 years. He is Board Certified in Internal Medicine, Pulmonary Medicine, Critical Care Medicine, and Sleep Medicine. He is a prolific writer, with dozens of peer-reviewed scientific articles and medical blog posts. He is a Physician Leader and published author. His latest book is "Code Blue," a medical thriller.

DR HESHAM A HASSABLLA

Medika Editor: Cardio and Pulmonary

Dr. Hesham A. Hassaballa is a NY Times featured Pulmonary and Critical Care Medicine specialist in clinical practice for over 20 years. He is Board Certified in Internal Medicine, Pulmonary Medicine, Critical Care Medicine, and Sleep Medicine.

He is a prolific writer, with dozens of peer-reviewed scientific articles and medical blog posts. He is a Physician Leader and published author. His latest book is "Code Blue," a medical thriller.

Medika are also thrilled to announce Hesham has recently joined our team as an Editor for BeingWell, Medika's publication on Medium

CONNECT WITH HESHAM

Website

Twitter

LinkedIn

All articles, information and publications featured by the author on thees pages remain the property of the author. Creative Commons does not apply and should you wish to syndicate, copy or reproduce, in part or in full, any of the content from this author, please contact Medika directly.